Trial · NCT03508687
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Fasting Serum Triglyceride (at 12 Weeks) | Baseline to week 12 | This is measured by percent change in fasting serum triglyceride from baseline to week 12 |
| Secondary | Change in Fasting Serum Triglycerides (Through 24 Weeks) | Baseline, week 6 and week 12, week 24 | This is measured by change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12 |
| Secondary | Percent Change in Fasting Serum Triglycerides (Through 24 Weeks) | Baseline, week 6 and week 12, week 24 | This is measured by percent change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12 |
| Secondary | Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Baseline, week 12, week 24 | This is measured by change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24 |
| Secondary | Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) | Baseline, week 12, week 24 | This is measured by percent change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24 |
| Secondary | Change in Liver Fibrosis | Baseline, Week 12, and Week 24 | This is measured by change in liver fibrosis using MR-elastography from baseline to week 12 and week 24 |
| Secondary | Percent Change in Liver Fibrosis | Baseline, Week 12, and Week 24 | This is measured by percent change in liver fibrosis using MR-elastography from baseline to week 12 and week 24 |
| Secondary | Change in NAS (Non-alcoholic Steatohepatitis) | Baseline to week 24 | This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease. |
| Secondary | Percent Change in NAS (Non-alcoholic Steatohepatitis) | Baseline to week 24 | This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease. |
| Secondary | Change in Cholesterol | Baseline, week 6 and week 12, week 24 | This will be measured by change in total, HDL and LDL levels in mg/dL |
| Secondary | Percent Change in Cholesterol | Baseline, week 6 and week 12, week 24 | This will be measured as percent change in total, HDL and LDL levels in mg/dL. |
| Secondary | Change in Apolipoprotein | Baseline, week 6 and week 12, week 24 | This will be measured by change in apolipoprotein A and B in mg/dL |
| Secondary | Percent Change in Apolipoprotein | Baseline, week 6 and week 12, week 24 | This will be measured by percent change in apolipoprotein A and B in mg/dL |
| Secondary | Change in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline, week 12, week 24 | This is measured by change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24 |
| Secondary | Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) | Baseline, week 12, week 24 | This is measured by percent change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24 |
| Secondary | Change in Alanine Aminotransferase (ALT) | Baseline, week 12, week 24 | This is measured by change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24 |
| Secondary | Percent Change in Alanine Aminotransferase (ALT) | Baseline, week 12, week 24 | This is measured by percent change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24 |
| Secondary | Change in Aspartate Aminotransferase (AST) | Baseline, week 12, week 24 | This is measured by change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24 |
| Secondary | Percent Change in Aspartate Aminotransferase (AST) | Baseline, week 12, week 24 | This is measured by percent change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03508687/registered